Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2025 07:00 ET | Source: GenVivo, Inc.

GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Systemic Cancer Immunotherapy, at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GEN2 was evaluated in adult patients with advanced solid tumors in an intravenous dose escalation Phase 1 study GEN2 is well-tolerated, with no Dose Limiting Toxicity or treatment-related...